Patents Assigned to VGX PHARMACEUTICALS, LLC
-
Publication number: 20190167983Abstract: Devices and methods for delivering an electropermeabilizing pulse of electric energy to a tissue surface to enable delivery into cells in the tissue therapeutic substances. The device incorporates a source capable of generating a sufficient voltage potential to deliver a spark across a gap and delivers same to the tissue surface.Type: ApplicationFiled: February 11, 2019Publication date: June 6, 2019Applicant: VGX Pharmaceuticals, LLCInventors: Thomas Joseph KARDOS, Stephen Vincent KEMMERRER, Rune KJEKEN, Kate BRODERICK, Jay MCCOY, Michael P. FONS
-
Patent number: 10232173Abstract: Devices and methods for delivering an electropermeabilizing pulse of electric energy to a tissue surface to enable delivery into cells in the tissue therapeutic substances. The device incorporates a source capable of generating a sufficient voltage potential to deliver a spark across a gap and delivers same to the tissue surface.Type: GrantFiled: April 16, 2010Date of Patent: March 19, 2019Assignee: VGX Pharmaceuticals, LLCInventors: Thomas Joseph Kardos, Stephen Vincent Kemmerer, Rune Kjeken, Kate Broderick, Jay McCoy, Michael P Fons
-
Patent number: 8961994Abstract: Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.Type: GrantFiled: November 17, 2009Date of Patent: February 24, 2015Assignee: VGX Pharmaceuticals, LLCInventors: Mathura P. Ramanathan, Niranjan Y Sardesai
-
Patent number: 8835620Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.Type: GrantFiled: January 12, 2009Date of Patent: September 16, 2014Assignee: VGX Pharmaceuticals, LLCInventors: Mathura P. Ramanathan, Niranjan Sardesai
-
Publication number: 20120046598Abstract: Devices and methods for delivering an electropermeabilizing pulse of electric energy to a tissue surface to enable delivery into cells in the tissue therapeutic substances. The device incorporates a source capable of generating a sufficient voltage potential to deliver a spark across a gap and delivers same to the tissue surface.Type: ApplicationFiled: April 16, 2010Publication date: February 23, 2012Applicant: VGX PHARMACEUTICALS, LLCInventors: Thomas Joseph Kardos, Stephen Vincent Kemmerer, Rune Kjeken, Kate Broderick, Jay McCoy, Michael P Fons
-
Publication number: 20110070640Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid with a mutated origin of replication (e.g. “mut” family of plasmids) comprising a therapeutic element, and a replication element. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.Type: ApplicationFiled: November 17, 2010Publication date: March 24, 2011Applicant: VGX PHARMACEUTICALS, LLCInventors: Ruxandra DRAGHIA-AKLI, Melissa POPE
-
Publication number: 20110034544Abstract: Compositions and kits comprising a nucleotide sequence that encodes GHRH and a nucleotide sequence that encodes GnRH and compositions and kits comprising a GHRH protein and GnRH protein are disclosed. Use of such compositions and kits in methods of enhancing fertility in mammals comprising the step of administering said compositions to the mammal are disclosed.Type: ApplicationFiled: March 6, 2009Publication date: February 10, 2011Applicant: VGX PHARMACEUTICALS, LLCInventors: Ruxandra Draghia-Akli, Amir Khan, Patricia Brown
-
Publication number: 20100291144Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.Type: ApplicationFiled: January 12, 2009Publication date: November 18, 2010Applicant: VGX PHARMACEUTICALS, LLCInventors: Mathura P Ramanathan, Niranjan Y Sardesai
-
Publication number: 20100247437Abstract: The present invention is directed towards materials and methods of delivering biomolecules to cells that define an organ, and the organ being in situ, and electroporating cells defining the organ by delivering to the cells an amount of energy effective to electroporate the cells. The present invention is also directed towards materials and methods of expressing heterologous polypeptides in organs of a subject and electroporating cells defining the organ by delivering to the cells an amount of energy effective to electroporate the cells.Type: ApplicationFiled: September 24, 2008Publication date: September 30, 2010Applicant: VGX PHARMACEUTICALS, LLCInventor: Ruxandra Draghia-Akli